AbbVie Inc. is 220.3x more valuable than Avidity Biosciences, Inc. by market capitalization ($399.47 B vs $1.81 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | RNA | ABBV |
|---|---|---|
| Market cap | $1.81 B | $399.47 B |
| US-listed rank | #2174 | #28 |
| Revenue (latest FY) | $18.75M | $61.16B |
| Net income (latest FY) | -$684.63M | $4.23B |
| Net margin | -3650.4% | 6.9% |
| P/E (trailing FY) | - | 94.5 |
| SEC filings | 547 | 1,008 |
AbbVie Inc. is 220.3x more valuable than Avidity Biosciences, Inc. by market capitalization ($399.47 B vs $1.81 B).
In their latest fiscal years, Avidity Biosciences, Inc. reported $18.75M in revenue while AbbVie Inc. reported $61.16B.
Full pages: Avidity Biosciences, Inc. and AbbVie Inc., or browse the full rankings.